Blair William & Co. IL Has $606,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Key Points

• Blair William & Co. IL increased its holdings in Recursion Pharmaceuticals by 854.2% in Q1, now owning 114,500 shares valued at $606,000.
• Recursion Pharmaceuticals reported a loss of $0.41 per share for the last quarter, missing consensus estimates, but had a 33.3% increase in revenue compared to the previous year.
• Analysts rate Recursion Pharmaceuticals with an average rating of "Hold" and a target price of around $7.00, with research from Needham maintaining a "buy" rating and an $8.00 target.

Blair William & Co. IL boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 854.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 114,500 shares of the company's stock after buying an additional 102,500 shares during the quarter. Blair William & Co. IL's holdings in Recursion Pharmaceuticals were worth $606,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. R Squared Ltd acquired a new stake in Recursion Pharmaceuticals in the 1st quarter worth $72,000. PNC Financial Services Group Inc. boosted its position in shares of Recursion Pharmaceuticals by 34.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 13,229 shares of the company's stock valued at $70,000 after acquiring an additional 3,409 shares in the last quarter. Blueshift Asset Management LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $70,000. Moors & Cabot Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $232,000. Finally, LPL Financial LLC boosted its position in shares of Recursion Pharmaceuticals by 15.6% during the 1st quarter. LPL Financial LLC now owns 425,090 shares of the company's stock valued at $2,249,000 after acquiring an additional 57,305 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX traded up $0.29 during mid-day trading on Wednesday, reaching $5.70. 23,453,313 shares of the company's stock were exchanged, compared to its average volume of 25,100,377. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The firm has a market capitalization of $2.32 billion, a PE ratio of -3.20 and a beta of 0.93. The business's fifty day simple moving average is $5.44 and its two-hundred day simple moving average is $5.87. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%. The business had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. During the same period in the prior year, the business posted ($0.40) earnings per share. Recursion Pharmaceuticals's revenue was up 33.3% compared to the same quarter last year. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Needham & Company LLC restated a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.